Results 101 to 110 of about 2,201,777 (199)

Erdafitinib Overcomes FGFR3-TACC3–Mediated Resistance to Osimertinib [PDF]

Journal of Thoracic Oncology, 2020
Eric B, Haura, J Kevin, Hicks, Theresa A, Boyle   +2 more
openaire   +2 more sources

Treating EGFR mutation resistance in non-small cell lung cancer – role of osimertinib

, 2017
Valentina Mazza,1 Federico Cappuzzo1,2 1Department of Oncology-Hematology, 2Department of Medical Oncology, AUSL Romagna, Ravenna, Italy Abstract: The discovery of mutations in EGFR significantly changed the treatment paradigm of patients with EGFR ...
Cappuzzo F, Mazza V
core  

Optimizing Osimertinib for NSCLC: Targeting Resistance and Exploring Combination Therapeutics

Cancers
Non-small-cell lung cancer (NSCLC) is a leading cause of cancer-related deaths worldwide, with epidermal growth factor receptor (EGFR) mutations present in a substantial proportion of patients. Third-generation EGFR tyrosine kinase inhibitors (EGFR TKI), exemplified by osimertinib, have dramatically improved outcomes by effectively targeting the T790M ...
Yan-You Liao, Chia-Luen Tsai, Hsiang-Po Huang   +2 more
openaire   +2 more sources

DNA topoisomerase II inhibition potentiates osimertinib’s therapeutic efficacy in EGFR-mutant non–small cell lung cancer models

The Journal of Clinical Investigation
Development of effective strategies to manage the inevitable acquired resistance to osimertinib, a third-generation EGFR inhibitor for the treatment of EGFR-mutant (EGFRm) non–small cell lung cancer (NSCLC), is urgently needed.
Zhen Chen, Karin A. Vallega, Dongsheng Wang, Zihan Quan, Songqing Fan, Qiming Wang, Ticiana Leal, Suresh S. Ramalingam, Shi-Yong Sun   +8 more
doaj   +1 more source

A Hybrid Protein-Oxygen Nanomedicine Overcomes Osimertinib Resistance in NSCLC via HIF-1α/VEGF/EGFR Inhibition

Guanming Jiang,1,* Xuyi Liu,2,3,* Dou Zhang,2,3,* Zhenying Diao,2,3 Xiaojun Yang,1 Qinquan Tan,1 Shiyuan Chen,1 Wan Zhang,1 Xiumao Yin,1 Ting Yin,2,3 Xiaozhen Wang,4 Jianping Zhou5 1Department of Oncology, Tenth Affiliated ...
Liu X, Yang X, Zhang W, Yin X, Zhang D, Diao Z, Yin T, Jiang G, Wang X, Chen S, Tan Q, Zhou J   +11 more
core  

Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy

, 2017
Mariacarmela Santarpia,1 Alessia Liguori,1 Niki Karachaliou,2 Maria Gonzalez-Cao,3 Maria Grazia Daffinà,1 Alessandro D’Aveni,1 Grazia Marabello,1 Giuseppe Altavilla,1 Rafael Rosell3–5 1Medical Oncology Unit, Department of Human ...
Rosell R, D'Aveni A, Daffinà MG, Marabello G, Santarpia M, Liguori A, Karachaliou N, Gonzalez-Cao M, Altavilla G   +8 more
core  

Anlotinib Plus Osimertinib in Osimertinib‐Resistant Nonsquamous Nonsmall Cell Lung Cancer With Gradual Progression: A Retrospective Study

Thoracic Cancer
ABSTRACTBackgroundPrevious studies have shown that anlotinib plus third‐generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) overcome acquired resistance to EGFR‐TKIs in patients with advanced EGFR‐mutant nonsmall cell lung cancer (NSCLC).
Yu Hua, Minghui Liu, Boshi Li, Hongbing Zhang, Zihe Zhang, Yanan Wang, Jinghao Liu, Xin Li, Yongwen Li, Sen Wei, Hongyu Liu, Jun Chen   +11 more
openaire   +3 more sources

Molecular Evolutionary Insights Allow a Sequential Precision Medicine Strategy for Acquired Osimertinib Resistance in EGFR Mutant Non‐Small Cell Lung Cancer: Lessons From Longitudinal Tumor Sampling

Clinical Case Reports
Osimertinib acquired resistance is a significant clinical challenge in the treatment of metastatic epidermal growth factor (EGFR) mutated non‐small cell lung cancer (NSCLC) patients and strategies to overcome it include further tumor sequencing, to ...
Foteini Kalofonou, Zayd Tippu, Maya Ramesh, Mira Pemmanda, Sanjay Popat   +4 more
doaj   +1 more source

Revealing underlying regulatory mechanisms of LINC00313 in Osimertinib-resistant LUAD cells by ceRNA network analysis

Translational Oncology
Background: Osimertinib, a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), is the preferred treatment for EGFR-mutated lung cancer. However, acquired resistance inevitably develops.
Dandan Ding, Chenguang Xu, Jufeng Zhang, Ying Zhang, Lipeng Xue, Jingjing Song, Zhiming Luo, Xiaoyu Hong, Jian Wang, Weicheng Liang, Xingyang Xue   +10 more
doaj   +1 more source

CircSPINT2 confers sensitivity to osimertinib via hsa-miR-1296-3p/RBP1 axis and inhibits NSCLC progression

Molecular Therapy: Oncology
Lung adenocarcinoma (LUAD) is the most common type of lung cancer. Prolonged treatment of LUAD with 1st/2nd generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) promotes the emergence of secondary EGFR T790M mutation ...
Nalini Devi Verusingam, Aliaksandr A. Yarmishyn, Min-Long Tsai, Ping-Hsing Tsai, Yi-Chen Chen, Chih-Ling Yeh, Soon-Keng Cheong, Po-Kuei Hsu, Shih-Hwa Chiou, Alan Han-Kiat Ong, Mong-Lien Wang   +10 more
doaj   +1 more source